Alpha-fetoprotein (AFP)-producing ovarian tumor in an elderly woman. 2009

Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
Department of Obstetrics and Gynecology, Jikei University School of Medicine, Aoto Hospital, Tokyo, Japan. isonishi@jikei.ac.jp

Apart from typical yolk sac tumors, ovarian tumors with elevated alfa-fetoprotein (AFP) are uncommon and the differential diagnosis needs to consider the hepatoid pattern of a yolk sac tumor, hepatocellular carcinoma metastatic to the ovary, hepatoid carcinoma, and other epithelial ovarian tumors. We report here an AFP-producing ovarian tumor with uncertain pathological diagnosis, which was extremely responsive to chemotherapy. A 59-year-old Japanese woman presented with lower abdominal distension and was found to have a left ovarian mass on pelvic examination and magnetic resonance imaging (MRI) scan. Laboratory tests showed serum AFP, 73 687 ng/ml; carbohydrate antigen 125 (CA125), 1599 U/ml; and carcinoembryonic antigen (CEA), 13.9 ng/ml. Total hysterectomy with bilateral salpingo-oophorectomy, partial omentectomy, and low anterior resection of the rectum was performed, without any residual macroscopic tumor. Microscopically, the tumor was characterized by a hepatoid carcinomatous component composed of solid sheets of large eosinophilic cells with pleomorphic nuclei. The pathological stage was pT2N0M0. Tumor cells were diffusely immunoreactive for AFP and cytokeratin (CAM5.2), but monoclonal CEA and CA19-9 were focally positive in the cytoplasm, while CA125 was negative. The patient was treated postoperatively with three cycles of chemotherapy consisting of bleomycin, etoposide, and cisplatin; with this regimen, serum AFP decreased to 16 ng/ml from 12 600 ng/ml just before the initiation of chemotherapy. The patient received secondary cytoreductive surgery of systemic lymphadenectomy, which revealed no evidence of residual tumor.

UI MeSH Term Description Entries
D007044 Hysterectomy Excision of the uterus. Hysterectomies
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D009852 Omentum A double-layered fold of peritoneum that attaches the STOMACH to other organs in the ABDOMINAL CAVITY. Omentums
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010052 Ovariectomy The surgical removal of one or both ovaries. Castration, Female,Oophorectomy,Bilateral Ovariectomy,Bilateral Ovariectomies,Castrations, Female,Female Castration,Female Castrations,Oophorectomies,Ovariectomies,Ovariectomies, Bilateral,Ovariectomy, Bilateral
D012007 Rectum The distal segment of the LARGE INTESTINE, between the SIGMOID COLON and the ANAL CANAL. Rectums
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas

Related Publications

Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
April 2024, Cureus,
Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
November 2017, Gan to kagaku ryoho. Cancer & chemotherapy,
Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
October 2021, Archives of gynecology and obstetrics,
Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
November 2017, Oncotarget,
Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
May 1995, Hinyokika kiyo. Acta urologica Japonica,
Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
January 1986, Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg,
Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
September 1978, South Dakota journal of medicine,
Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
June 1979, Nihon rinsho. Japanese journal of clinical medicine,
Seiji Isonishi, and Asako Ogura, and Takako Kiyokawa, and Michiko Suzuki, and Shiro Kunito, and Masanori Hirama, and Toshiaki Tachibana, and Kazuhiko Ochiai, and Tadao Tanaka
March 1981, Ceskoslovenska gynekologie,
Copied contents to your clipboard!